Cerus Corp. (CERS)

5.67
0.01 0.18
NASDAQ : Health Technology
Prev Close 5.68
Open 5.69
Day Low/High 5.66 / 5.79
52 Wk Low/High 3.77 / 8.05
Volume 641.63K
Avg Volume 904.80K
Exchange NASDAQ
Shares Outstanding 135.69M
Market Cap 766.64M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of CERS August 16th Options Trading

First Week Of CERS August 16th Options Trading

Investors in Cerus Corp. saw new options begin trading this week, for the August 16th expiration.

Cerus Announces First Patient Enrolled In The Phase 3 ReCePI Study

Cerus Announces First Patient Enrolled In The Phase 3 ReCePI Study

Cerus Corporation (Nasdaq:CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study to evaluate the efficacy and safety of the INTERCEPT Blood...

Cerus Completes CE Mark Submission For INTERCEPT Red Blood Cells

Cerus Completes CE Mark Submission For INTERCEPT Red Blood Cells

Cerus Corporation (Nasdaq:CERS) today announced that it has filed for CE Mark registration for the Company's INTERCEPT red blood cell (RBC) system.

American Red Cross Receives Biologics License Application Approval For INTERCEPT Platelets

American Red Cross Receives Biologics License Application Approval For INTERCEPT Platelets

Cerus Corporation (Nasdaq:CERS) announced today that the American Red Cross has received approval by the U.

Cerus Supports FDA's Continuing Efforts To Enhance The Safety Of The U.S. Platelet Supply

Cerus Supports FDA's Continuing Efforts To Enhance The Safety Of The U.S. Platelet Supply

Cerus Corporation (Nasdaq:CERS) announced today the issuance of a new U.S.

Relative Strength Alert For Cerus

Relative Strength Alert For Cerus

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cerus To Present At The 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Cerus To Present At The 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Cerus Corporation (Nasdaq:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, and Vivek Jayaraman, Cerus' chief commercial officer, are scheduled to present a corporate update at the 2018 Canaccord Genuity...

CERS Makes Notable Cross Below Critical Moving Average

CERS Makes Notable Cross Below Critical Moving Average

In trading on Monday, shares of Cerus Corp. crossed below their 200 day moving average of $6.19, changing hands as low as $5.83 per share.

Cerus To Present At The 2018 Stephens NY Investment Conference

Cerus To Present At The 2018 Stephens NY Investment Conference

Cerus Corporation (Nasdaq:CERS) announced today that William 'Obi' Greenman, Cerus' president and chief executive officer, and Kevin Green, Cerus' vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018...

Cerus Corporation Reports Third Quarter 2018 Results

Cerus Corporation Reports Third Quarter 2018 Results

Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2018.

Cerus Receives FDA Breakthrough Device Designation For Pathogen-Reduced Cryoprecipitate

Cerus Receives FDA Breakthrough Device Designation For Pathogen-Reduced Cryoprecipitate

Cerus Corporation (Nasdaq:CERS) announced today that the U.S.

First Week Of CERS December 21st Options Trading

First Week Of CERS December 21st Options Trading

Investors in Cerus Corp. saw new options begin trading this week, for the December 21st expiration.

Cerus To Release Third Quarter 2018 Results On November 1, 2018

Cerus To Release Third Quarter 2018 Results On November 1, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market.

Cerus To Provide Update To Development Programs And Outline Growth Strategy At 2018 Institutional Investor Meeting

Cerus To Provide Update To Development Programs And Outline Growth Strategy At 2018 Institutional Investor Meeting

Cerus Corporation (Nasdaq: CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston.

Cerus Announces Schedule Of Presentations At The 2018 AABB Annual Meeting

Cerus Announces Schedule Of Presentations At The 2018 AABB Annual Meeting

Cerus Corporation (Nasdaq: CERS) announced today its schedule of key events and presentations at the 2018 AABB Annual Meeting which is taking place in Boston on October 13 through October 16.

Dr. Laurence Corash Recognized With The Prestigious Dale A. Smith Memorial Award

Dr. Laurence Corash Recognized With The Prestigious Dale A. Smith Memorial Award

Cerus Corporation (Nasdaq: CERS) today announced Dr. Laurence Corash, the Company's co-founder and chief scientific officer has been awarded the prestigious Dale A.

Notable Two Hundred Day Moving Average Cross - CERS

Notable Two Hundred Day Moving Average Cross - CERS

In trading on Wednesday, shares of Cerus Corp. crossed below their 200 day moving average of $5.96, changing hands as low as $5.90 per share.

Cerus Appoints Eric Bjerkholt To Board Of Directors

Cerus Appoints Eric Bjerkholt To Board Of Directors

Cerus Corporation (Nasdaq: CERS) today announced the appointment of Eric Bjerkholt to its Board of Directors.

Cerus Enters Oversold Territory (CERS)

Cerus Enters Oversold Territory (CERS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Cerus To Host Institutional Investor Meeting

Cerus To Host Institutional Investor Meeting

Cerus Corporation (Nasdaq: CERS) today announced that it will host an Institutional Investor Meeting on Tuesday, October 16, 2018 in Boston, Massachusetts.

Cerus To Present At The Cantor Fitzgerald 2018 Global Healthcare Conference

Cerus To Present At The Cantor Fitzgerald 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that William 'Obi' Greenman, Cerus' president and chief executive officer, will present and provide a corporate update at the Cantor Fitzgerald 2018 Global Healthcare Conference in New York City on Tuesday,...

Cerus Appoints Timothy L. Moore To Board Of Directors

Cerus Appoints Timothy L. Moore To Board Of Directors

Cerus Corporation (Nasdaq:CERS) today announced the appointment of Timothy L. Moore to its Board of Directors.

Cerus To Present At The Baird 2018 Global Healthcare Conference

Cerus To Present At The Baird 2018 Global Healthcare Conference

Cerus Corporation (Nasdaq: CERS) today announced that Kevin D. Green, Cerus' vice president, finance and chief financial officer, will present and provide a corporate update at the Baird 2018 Global Healthcare Conference in New York City on Thursday,...

Cerus Corporation Reports Second Quarter 2018 Results

Cerus Corporation Reports Second Quarter 2018 Results

Cerus Corporation (Nasdaq: CERS) announced today financial results for the second quarter ended June 30, 2018, and raised its full year guidance for product revenue.

Cerus To Release Second Quarter 2018 Results On August 2, 2018

Cerus To Release Second Quarter 2018 Results On August 2, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its second quarter results will be released on Thursday, August 2, 2018, after the close of the stock market.

New Navy Policy Implements Full Adoption Of Pathogen-Reduced Apheresis Platelets Collected At U.S. Navy Blood Donor Centers

New Navy Policy Implements Full Adoption Of Pathogen-Reduced Apheresis Platelets Collected At U.S. Navy Blood Donor Centers

Cerus Corporation (Nasdaq: CERS) announced today that the U.S.

First Week Of CERS February 2019 Options Trading

First Week Of CERS February 2019 Options Trading

Investors in Cerus Corp. saw new options become available this week, for the February 2019 expiration.

Cerus Presents Results Of European Phase 3 Chronic Anemia Study At The 23rd Congress Of European Hematology Association

Cerus Presents Results Of European Phase 3 Chronic Anemia Study At The 23rd Congress Of European Hematology Association

Cerus Corporation (Nasdaq: CERS) announced that results from SPARC, the Company's European Phase 3 study evaluating the efficacy and safety of INTERCEPT-treated red blood cells (RBCs) in thalassemia major patients, were presented today at the 23 rd...

TheStreet Quant Rating: D- (Sell)